New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
PR Newswire Asia
MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following..